repaglinide

High Alert

Type 2 diabetes mellitus, with diet and exercise; may be used with metformin, rosiglitazone, or pioglitazone.

Contraindicated in:

Hypersensitivity
Lactation: Lactation
Diabetic ketoacidosis
Type 1 diabetes
Concurrent use of gemfibrozil.

Use Cautiously in:

Impaired liver function (longer dosing intervals may be necessary)
Severe renal impairment (dose ↓ recommended)
Geri: Consider age-related ↓ in renal/hepatic/cardiovascular function
OB: Pedi: Safety not established; insulin recommended to control diabetes during pregnancy.

CV: angina, chest pain.

Endo: hypoglycemia, hyperglycemia.

Drug-Drug:

Ketoconazole, miconazole, gemfibrozil, itraconazole, clarithromycin, and erythromycin may ↓ metabolism and ↑ risk of hypoglycemia; concurrent use with gemofibrozil contraindicated.
Levels and effects may also be ↑ by NSAIDs, clopidogrel, cyclosporine, hormonal contraceptives, simvastatin, sulfonamides, chloramphenicol, warfarin, probenecid, deferasirox, MAO inhibitors, and beta blockers; avoid concurrent use with clopidogrel, if possible (if not possible, ↓ dose of repaglinide).
Effects may be ↓ by corticosteroids, phenothiazines, thyroid preparations, estrogens, hormonal contraceptives, phenytoin, nicotinic acid, sympathomimetics, isoniazid, and calcium channel blockers.

Drug-Natural Products:

Glucosamine may worsen blood glucose control.
Chromium and coenzyme Q-10 may produce ↑ hypoglycemic effects.

(Generic available)

Tablets: 0.5 mg; 1 mg; 2 mg;
In combination with: metformin (PrandiMet); see Appendix [not included in this PDA edition].

PO (Adults): 0.5–4 mg taken before meals (not to exceed 16 mg/day); Concurrent use with cyclosporine — Not to exceed 6 mg/day;Concurrent use with clopidogrel — Initiate at 0.5 mg taken before meals (not to exceed 4 mg/day).

Renal Impairment

PO (Adults): Severe renal impairment — start with 0.5 mg/day and titrate carefully.

Stimulates the release of insulin from pancreatic beta cells by closing potassium channels, which results in the opening of calcium channels in beta cells. This is followed by release of insulin.

Therapeutic Effects:

Lowering of blood glucose levels.

Therapeutic Classification: antidiabetics

Pharmacologic Classification: meglitinides

Absorption: Well absorbed (56%) following oral administration.

Distribution: Unknown.

Protein Binding: >98%.

Metabolism/Excretion: Mostly metabolized by the liver; metabolites are excreted primarily in feces.

Half-life: 1 hr.

ROUTE	ONSET	PEAK	DURATION
PO	within 30 min	60–90 min	<4 hr

Instruct patient to take repaglinide before each meal, exactly as directed.
Explain to patient that repaglinide helps control hyperglycemia but does not cure diabetes. Therapy is usually long term.
Encourage patient to follow prescribed diet, medication, and exercise regimen to prevent hyperglycemic or hypoglycemic episodes.
Review signs of hypoglycemia and hyperglycemia with patient. If hypoglycemia occurs, advise patient to take a glass of orange juice or 2–3 tsp of sugar, honey, or corn syrup dissolved in water, and notify health care professional.
Instruct patient in proper testing of blood glucose. These tests should be monitored closely during periods of stress or illness and a health care professional notified if significant changes occur.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications and alcohol.
Advise patient to inform health care professional of medication regimen prior to treatment or surgery.
Insulin is the recommended method of controlling blood glucose during pregnancy. Counsel female patients to use a form of contraception other than oral contraceptives and to notify health care professional promptly if pregnancy is planned or suspected.
Advise patient to carry a form of sugar (sugar packets, candy) and identification describing disease process and medication regimen at all times.
Emphasize the importance of routine follow-up exams and regular testing of blood glucose and glycosylated hemoglobin.

NDC Code^*

0169- Novo Nordisk
0169-0081- Prandin 0169-0081-80- 12 TABLET in 1 BOTTLE, PLASTIC (0169-0081-80)

0169- Novo Nordisk
0169-0081- Prandin 0169-0081-81- 100 TABLET in 1 BOTTLE, PLASTIC (0169-0081-81)

0169- Novo Nordisk
0169-0081- Prandin 0169-0081-82- 500 TABLET in 1 BOTTLE, PLASTIC (0169-0081-82)

0574- Paddock Laboratories, LLC
0574-0240- Repaglinide 0574-0240-01- 100 TABLET in 1 BOTTLE (0574-0240-01)

0574- Paddock Laboratories, LLC
0574-0241- Repaglinide 0574-0241-01- 100 TABLET in 1 BOTTLE (0574-0241-01)

0574- Paddock Laboratories, LLC
0574-0242- Repaglinide 0574-0242-01- 100 TABLET in 1 BOTTLE (0574-0242-01)

51991- Breckenridge Pharmaceutical, Inc.
51991-853- REPAGLINIDE 51991-853-01- 100 TABLET in 1 BOTTLE (51991-853-01)

51991- Breckenridge Pharmaceutical, Inc.
51991-854- REPAGLINIDE 51991-854-01- 100 TABLET in 1 BOTTLE (51991-854-01)

51991- Breckenridge Pharmaceutical, Inc.
51991-855- REPAGLINIDE 51991-855-01- 100 TABLET in 1 BOTTLE (51991-855-01)

57237- Rising Health, LLC
57237-157- Repaglinide 57237-157-01- 100 TABLET in 1 BOTTLE (57237-157-01)

57237- Rising Health, LLC
57237-157- Repaglinide 57237-157-05- 500 TABLET in 1 BOTTLE (57237-157-05)

57237- Rising Health, LLC
57237-158- Repaglinide 57237-158-01- 100 TABLET in 1 BOTTLE (57237-158-01)

57237- Rising Health, LLC
57237-158- Repaglinide 57237-158-05- 500 TABLET in 1 BOTTLE (57237-158-05)

57237- Rising Health, LLC
57237-159- Repaglinide 57237-159-01- 100 TABLET in 1 BOTTLE (57237-159-01)

57237- Rising Health, LLC
57237-159- Repaglinide 57237-159-05- 500 TABLET in 1 BOTTLE (57237-159-05)

57664- Sun Pharmaceutical Industries, Inc.
57664-745- Repaglinide 57664-745-13- 500 TABLET in 1 BOTTLE (57664-745-13)

57664- Sun Pharmaceutical Industries, Inc.
57664-745- Repaglinide 57664-745-18- 1000 TABLET in 1 BOTTLE (57664-745-18)

57664- Sun Pharmaceutical Industries, Inc.
57664-745- Repaglinide 57664-745-88- 100 TABLET in 1 BOTTLE (57664-745-88)

57664- Sun Pharmaceutical Industries, Inc.
57664-747- Repaglinide 57664-747-13- 500 TABLET in 1 BOTTLE (57664-747-13)

57664- Sun Pharmaceutical Industries, Inc.
57664-747- Repaglinide 57664-747-18- 1000 TABLET in 1 BOTTLE (57664-747-18)

57664- Sun Pharmaceutical Industries, Inc.
57664-747- Repaglinide 57664-747-88- 100 TABLET in 1 BOTTLE (57664-747-88)

60429- Golden State Medical Supply, Inc.
60429-484- REPAGLINIDE 60429-484-01- 100 TABLET in 1 BOTTLE (60429-484-01)

60429- Golden State Medical Supply, Inc.
60429-485- REPAGLINIDE 60429-485-01- 100 TABLET in 1 BOTTLE (60429-485-01)

60429- Golden State Medical Supply, Inc.
60429-486- REPAGLINIDE 60429-486-01- 100 TABLET in 1 BOTTLE (60429-486-01)

60846- Amneal Pharmaceuticals LLC
60846-882- Prandin 60846-882-01- 100 TABLET in 1 BOTTLE (60846-882-01)

60846- Amneal Pharmaceuticals LLC
60846-884- Prandin 60846-884-01- 100 TABLET in 1 BOTTLE (60846-884-01)

65862- Aurobindo Pharma Limited
65862-670- Repaglinide 65862-670-01- 100 TABLET in 1 BOTTLE (65862-670-01)

65862- Aurobindo Pharma Limited
65862-670- Repaglinide 65862-670-05- 500 TABLET in 1 BOTTLE (65862-670-05)

65862- Aurobindo Pharma Limited
65862-670- Repaglinide 65862-670-99- 1000 TABLET in 1 BOTTLE (65862-670-99)

65862- Aurobindo Pharma Limited
65862-671- Repaglinide 65862-671-01- 100 TABLET in 1 BOTTLE (65862-671-01)

65862- Aurobindo Pharma Limited
65862-671- Repaglinide 65862-671-05- 500 TABLET in 1 BOTTLE (65862-671-05)

65862- Aurobindo Pharma Limited
65862-671- Repaglinide 65862-671-99- 1000 TABLET in 1 BOTTLE (65862-671-99)

65862- Aurobindo Pharma Limited
65862-672- Repaglinide 65862-672-01- 100 TABLET in 1 BOTTLE (65862-672-01)

65862- Aurobindo Pharma Limited
65862-672- Repaglinide 65862-672-05- 500 TABLET in 1 BOTTLE (65862-672-05)

65862- Aurobindo Pharma Limited
65862-672- Repaglinide 65862-672-99- 1000 TABLET in 1 BOTTLE (65862-672-99)

68084- American Health Packaging
68084-954- Repaglinide 68084-954-25- 30 BLISTER PACK in 1 BOX, UNIT-DOSE (68084-954-25) > 1 TABLET in 1 BLISTER PACK (68084-954-95)

68084- American Health Packaging
68084-967- Repaglinide 68084-967-25- 30 BLISTER PACK in 1 BOX, UNIT-DOSE (68084-967-25) > 1 TABLET in 1 BLISTER PACK (68084-967-95)

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Availability ⬆ ⬇

Route/Dosage ⬆ ⬇

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Classifications ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Canadian Brand Names ⬆ ⬇

Time/Action Profile ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

Code ⬆